Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections.

被引：0
|
作者：
Schneeweiss, S. [1 ]
Slomon, D. H. [1 ]
Korzenik, J. [2 ]
Canning, C. [1 ]
Bressler, B. [3 ]
机构：
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[3] Univ Vancouver, Vancouver, BC, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [1] Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Schneeweiss, Sebastian
    Solomon, Daniel
    Korzenik, Joshua
    Canning, Claire
    Bressler, Brian
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S62 - S62
  • [2] Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Bressler, Brian
    Korzenik, Joshua R.
    Canning, Claire
    Solomon, Daniel
    Schneeweiss, Sebastian
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A144 - A144
  • [3] Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Schneeweiss, S.
    Korzenik, J.
    Solomon, D. H.
    Canning, C.
    Lee, J.
    Bressler, B.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 253 - 264
  • [4] Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry Data
    Baldassano, Robert
    Colletti, Richard B.
    Cucchiara, Salvatore
    Dubinsky, Marla
    Escher, Johanna C.
    Faubion, William A.
    Fell, John
    Gold, Benjamin D.
    Griffiths, Anne M.
    Hyams, Jeffrey S.
    Koletzko, Sibylle
    Kugathasan, Subra
    Markowitz, James
    Ruemmele, Frank
    Veereman, Gigi
    Callegari, Peter
    Geldhof, Anja
    Molenda, Mark R.
    Wright, Richard
    Tang, Kezhen L.
    Winter, Harland S.
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S11 - S11
  • [5] HIGH EXPOSURE TO INFLIXIMAB IS ASSOCIATED WITH INCREASED RISK OF INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Landemaine, Amandine
    Petitcollin, Antoine
    Miard, Celine
    Brochard, Charlene
    Dewitte, Marie
    Laurent, Siproudhis
    Bouguen, Guillaume
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S628 - S629
  • [6] Use of infliximab in pediatric patients with inflammatory bowel disease
    Serrano, MS
    Schmidt-Sommerfeld, E
    Kilbaugh, TJ
    Brown, RF
    Udall, JN
    Mannick, EE
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 823 - 828
  • [7] The use of Infliximab in Older Inflammatory Bowel Disease Patients
    Moleski, Stephanie M.
    Lindenmeyer, Christina C.
    Kozuch, Patricia L.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S361 - S361
  • [8] REAL WORLD COMPARATIVE RISK OF SERIOUS INFECTION WITH ADALIMUMAB, VEDOLIZUMAB, AND INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Osterman, Mark T.
    Long, Millie D.
    Singh, Siddharth
    Meyer, Nicole
    Feng, Chaoling
    Higgins, Kate
    Hepp, Zsolt
    Arikan, Dilek
    Wang, Anthony
    Feagan, Brian G.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S365 - S365
  • [9] Infliximab: Use in inflammatory bowel disease
    Travassos W.J.
    Cheifetz A.S.
    [J]. Current Treatment Options in Gastroenterology, 2005, 8 (3) : 187 - 196
  • [10] Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease
    Wisniewski, Andrew
    Landman, Cecilia
    Kirchgesner, Julien
    Bourrier, Anne
    Nion-Larmurier, Isabelle
    Sokol, Harry
    Seksik, Philippe
    Cosnes, Jacques
    Beaugerie, Laurent
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S225 - S225
12345